Abstract:Background: Diabetes is a growing global health crisis that requires effective therapeutic strategies to optimize treatment outcomes. This study aims to address this challenge by developing and characterizing extended-release polymeric matrix tablets containing metformin hydrochloride (M-HCl), a first-line treatment for type 2 diabetes, and honokiol (HNK), a bioactive compound with potential therapeutic benefits. The objective is to enhance glycemic control and overall therapeutic outcomes through an innovative dual-drug delivery system. Methods: The tablets were formulated using hydrophilic polymers, such as Carbopol® 71G NF and Noveon® AA-1. The release kinetics of M-HCl and HNK were investigated through advanced mathematical models, including fractal and multifractal dynamics, to capture the non-linear and time-dependent release processes. Traditional kinetic models (zero-order, first-order, Higuchi equations) were also evaluated for comparison. In vitro dissolution studies were conducted to determine the release profiles of the active ingredients under varying polymer concentrations. Results: The study revealed distinct release profiles for the two active ingredients. M-HCl exhibited a rapid release phase, with 80% of the drug released within 4–7 h depending on polymer concentration. In contrast, HNK demonstrated a slower release profile, achieving 80% release after 9–10 h, indicating a greater sensitivity to polymer concentration. At shorter intervals, drug release followed classical kinetic models, while multifractal dynamics dominated at longer intervals. Higher polymer concentrations resulted in slower drug release rates due to the formation of a gel-like structure upon hydration, which hindered drug diffusion. The mechanical properties and stability of the matrix tablets confirmed their suitability for extended-release applications. Mathematical modeling validated the experimental findings and provided insights into the structural and time-dependent factors influencing drug release. Conclusions: This study successfully developed dual-drug extended-release matrix tablets containing metformin hydrochloride and honokiol, highlighting the potential of hydrophilic polymers to regulate drug release. The findings emphasize the utility of advanced mathematical models for predicting release kinetics and underscore the potential of these formulations to improve patient compliance and therapeutic outcomes in diabetes management.

Synchronized and Controlled Release of Metformin Hydrochloride/glipizide from Elementary Osmotic Delivery

Design and Evaluation of Compound Metformin/glipizide Elementary Osmotic Pump Tablets.

Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet.

Visualized analysis and evaluation of simultaneous controlled release of metformin hydrochloride and gliclazide from sandwiched osmotic pump capsule

In Vitro and in Vivo Evaluation of Two Extended Release Preparations of Combination Metformin and Glipizide.

Preparation and in Vitro Evaluation of Compound Pioglitazone Hydrochloride and Metformin Hydrochloride Controlled Release Tablets

Gastro-Floating Bilayer Tablets for the Sustained Release of Metformin and Immediate Release of Pioglitazone: Preparation and in Vitro/In Vivo Evaluation

Controlled porosity solubility modulated osmotic pump tablets of gliclazide

A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system

Preparation and in vivo / in vitro evaluation of a tri-layer tablet containing glimepiride / pioglitazone (IR), metformin (SR) with an isolation layer

Studies on controlled release effervescent osmotic pump tablets from Traditional Chinese Medicine Compound Recipe

Experimental and Theoretical Design on the Development of Matrix Tablets with Multiple Drug Loadings Aimed at Optimizing Antidiabetic Medication

Bilayer Matrix Tablets for Prolonged Actions of Metformin Hydrochloride and Repaglinide.

Development of a Robust Control Strategy for Fixed-Dose Combination Bilayer Tablets with Integrated Quality by Design, Statistical, and Process Analytical Technology Approach

Multifractal Analysis and Experimental Evaluation of MCM-48 Mesoporous Silica as a Drug Delivery System for Metformin Hydrochloride

Preparation and Investigation of Controlled-Release Glipizide Novel Oral Device with Three-Dimensional Printing.

Optimization of Extended Zero-order Release Gliclazide Tablets Using D-optimal Mixture Design

FORMULATION AND EVALUATION OF METFORMIN HYDROCHLORIDE SUSTAINED RELEASE MATRIX TABLETS

Full-factorial Desig n for Optimizing Formulation of Metformin Hydrochloride Extended-release Tablets and Investigation of Release Mechanism in Vitro

Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release

A Ph-Sensitive Controlled Dual-Drug Release from Meso-Macroporous Silica/multilayer-Polyelectrolytes Coated SBA-15 Composites